Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

About Theranexus

Theranexus is a biopharmaceutical company that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders. Theranexus' unique, patented technology is aimed at increasing the efficacy of CNS drugs that have already been approved and are available on the market.

Theranexus' technology is protected, unique, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes.



Theranexus announces the inclusion of the first patient in its phase 2 clinical trial evaluating its drug candidate THN102 in excessive daytime sleepiness (EDS) in patients with Parkinson's disease

16/07/2018
Download the PDF file (397 Ko)

Theranexus presents new data on the stimulating effect of its drug candidate THN 102

05/07/2018
Download PDF file (306 Ko)

Theranexus announces German Authorities approval for its phase 2 clinical trial in Parkinson's disease

26/06/2018
Download the PDF (375 Ko)

Theranexus announces the publication of a scientific article on the mechanism of action of drug candidate THN102 in the international journal of neuropsychopharmacology
22/05/2018
Download PDF file (262 Ko)

Theranexus publishes its cash position as at 31st March 2018
15/05/2018
Download PDF file (204 Ko)

September 5th 2018 :  Portzamparc Biotech conference, Paris

8 & 9 octobre 2018 : Large & MidCap Event, Paris

December 4th & 5th 2018 : European MidCap Event, Geneva

January 22nd 2019: Biomed conference, Paris